Protalix BioTherapeutics Inc. Q1 Loss decreases, but misses estimates

Protalix BioTherapeutics Inc. (PLX) released Loss for first quarter that decreased from the same period last year but missed the Street estimates.

The company’s bottom line totaled -$2.29 million, or -$0.05 per share. This compares with -$5.48 million, or -$0.14 per share, in last year’s first quarter.

Analysts on average had expected the company to earn $0.00 per share, according to figures compiled by Thomson Reuters. Analysts’ estimates typically exclude special items.

The company’s revenue for the quarter rose 42.1% to $16.09 million from $11.32 million last year.

Protalix BioTherapeutics Inc. earnings at a glance (GAAP) :

-Earnings (Q1): -$2.29 Mln. vs. -$5.48 Mln. last year.
-EPS (Q1): -$0.05 vs. -$0.14 last year.
-Analyst Estimates: $0.00
-Revenue (Q1): $16.09 Mln vs. $11.32 Mln last year.

Bristol Myers Squibb: Phase 3 CheckMate -901 Trial Fails To Meet Primary Endpoint

Bristol Myers Squibb (BMY) said the phase 3 CheckMate -901 trial, comparing Opdivo plus Yervoy to standard-of-care chemotherapy as a first-line treatment for patients with untreated unresectable or metastatic urothelial carcinoma, did not meet the primary endpoint of overall survival in patients whose tumor cells express PD-L1 1% at final analysis. An independent Data Monitoring Committee recommended that the trial continue to assess other primary and secondary endpoints, the company stated.

The company noted that the CheckMate -901 primary study and sub-study are ongoing, and
it will report results for these additional components of the study when available.

Emergent BioSolutions To Acquire TEMBEXA Rights From Chimerix For Up To $337.5 Mln + Royalties

Emergent BioSolutions Inc. (EBS) announced Monday that it has agreed to acquire Chimerix, Inc.’s (CMRX) exclusive worldwide rights to TEMBEXA (brincidofovir) for up to $337.5 million plus royalties.

This includes 225 million one-time upfront payment in cash upon closing and up to a total of $100 million in milestone payments contingent on the potential exercise by the U.S. government of procurement options following the base period.

Chimerix is also eligible to receive up to $12.5 million in regulatory milestones associated with the SymBio Pharmaceuticals Ltd. brincidofovir partnership to be assumed by Emergent.

Chimerix may also earn a 20% royalty on future gross profit of TEMBEXA sales in the U.S. and 15% outside of the U.S. during the exclusivity period of TEMBEXA.

TEMBEXA is the first antiviral approved by the U.S. Food and Drug Administration (FDA) for all age groups for the treatment of smallpox. It was approved in June 2021 and is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates.

Emergent anticipates that the transaction will be funded using currently available funds.

This transaction is subject to customary closing conditions. Subject to the satisfaction or waiver of the closing conditions, the companies expect the transaction to close as early as the end of the second quarter of 2022.

Diamondback To Acquire Publicly Held Common Units Of Rattler In All-stock Deal

Diamondback Energy, Inc. (FANG) and Rattler Midstream LP (RTLR) have entered into a definitive agreement for Diamondback to acquire all of the publicly held common units representing the limited partner interests in Rattler not already owned by Diamondback and its subsidiaries. Each public unitholder of Rattler would receive 0.113 of a share of common stock in Diamondback in exchange for each Rattler common unit owned.

Diamondback E&P LLC, a subsidiary of Diamondback and the holder of a majority of the outstanding units of Rattler, has voted its units to approve the deal.

Amended: PolarityTE Inc. Q1 Loss Narrows, But Misses Estimates

(Amended: Corrects headline to say loss decreased)

PolarityTE Inc. (PTE) revealed Loss for first quarter that decreased from last year but missed the Street estimates.

The company’s bottom line totaled -$3.77 million, or -$0.09 per share. This compares with -$17.41 million, or -$0.24 per share, in last year’s first quarter.

Excluding items, PolarityTE Inc. reported adjusted earnings of -$8.88 million or -$0.10 per share for the period.

Analysts on average had expected the company to earn -$0.08 per share, according to figures compiled by Thomson Reuters. Analysts’ estimates typically exclude special items.

The company’s revenue for the quarter fell 84.3% to $0.74 million from $4.71 million last year.

PolarityTE Inc. earnings at a glance (GAAP) :

-Earnings (Q1): -$3.77 Mln. vs. -$17.41 Mln. last year.
-EPS (Q1): -$0.09 vs. -$0.24 last year.
-Analyst Estimates: -$0.08
-Revenue (Q1): $0.74 Mln vs. $4.71 Mln last year.

Ariana Grande, Billie Eilish, Miley Cyrus & Many More Condemn Plan To Overturn Roe V. Wade

The New York Times on Friday published a full-page ad featuring 160 young artists and influencers advocating for reproductive freedom, including abortion rights.

They oppose the Supreme Court’s plan to overturn Roe v. Wade and end the U.S. constitutional right to an abortion, laid out in a recent leaked draft opinion.

As part of Planned Parenthood‘s #BansOffOurBodies campaign, the artists signed on to the Bans Off Our Bodies ad, which denounces the Supreme Court’s plan to eliminate the constitutional right to an abortion.

The signatories include Ariana Grande, Miley Cyrus, Billie Eilish, Kendall Jenner, Selena Gomez, Olivia Rodrigo, Megan Thee Stallion, Shawn Mendes, Camila Cabello, Demi Lovato, Halsey, Hailey Bieber, Camila Mendes, Lili Reinhart, FINNEAS, Phoebe Bridgers and Maia Mitchell.

These artists are encouraging their fans to join them in speaking out in support of the right to access sexual and reproductive health care, including abortion.

The celebrity-endorsed Bans Off Our Bodies ad runs in advance of Saturday’s May 14 Bans Off Our Bodies Day of Action. Hundreds of thousands of people are expected to turn out for rallies, marches, and events across the country in support of abortion rights.

(Photo: Planned Parenthood)